Editas Medicine (EDIT) Tops Q1 EPS by 15c

Editas Medicine (NASDAQ: EDIT) reported Q1 EPS of ($0.67), $0.15 better than the analyst estimate of ($0.82). Revenue for the quarter came in at $3.9 million versus the consensus estimate of $3.99 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance